Insomnia Products: Dayvigo
Defines authorization (initial and continuation) criteria, quantity limits, and duration of approval for lemborexant (Dayvigo) and related orexin receptor antagonists for treatment of adult insomnia characterized by difficulties with sleep onset and/or sleep maintenance. Applies to listed branded and generic forms of suvorexant, lemborexant, and daridorexant.
No material changes to clinical guidance or coverage were made.